YARS2: A Potential Drug Target and Biomarker for Tyrosine-TRNA Ligase

Target Name: YARS2

NCBI ID: G51067

YARS2

YARS2: A Potential Drug Target and Biomarker for Tyrosine-TRNA Ligase

Introduction

Tyrosine-tRNA ligase (YARS2) is a key enzyme in the regulation of protein synthesis in eukaryotic cells. This enzyme catalyzes the conversion of tyrosine to its amino acid precursor, tRNA, while also ensuring the correct loading of tRNA into the ribosome for protein synthesis. The defect in YARS2 has been implicated in various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. As a result, targeting YARS2 has become an attractive research focus to investigate its potential as a drug target or biomarker.

Drug Target Potential

The drug development process for YARS2 began with the identification of its potential target. YARS2 is an enzyme that is expressed in various tissues and cells, including brain, heart, and muscle. Therefore, potential drug targets can be identified by targeting the YARS2 protein in specific tissues or cells. One such potential target is the protein kinase B3 (PKB/AKT), which is known to be a downstream effector of YARS2.

The kinase B3 is a protein that is involved in various cellular processes, including cell survival, metabolism, and inflammation. It has been implicated in various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Therefore, targeting YARS2 and PKB/AKT with small molecules or antibodies have the potential to be a novel drug or biomarker.

Biomarker Potential

In addition to its potential as a drug target, YARS2 also has the potential as a biomarker for various diseases. The regulation of protein synthesis is a critical process that is affected by various factors, including mutations, RNA misprocessing, and protein misfolding. Therefore, changes in the level of YARS2 activity or its expression levels can be used as biomarkers for diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

YARS2 has been shown to be involved in the regulation of protein synthesis in various tissues and cells. For example, studies have shown that YARS2 is involved in the regulation of protein synthesis in brain cells, heart muscle cells, and cancer cells. Additionally, overexpression of YARS2 has been shown to increase the level of protein synthesis in certain tissues, which could be used as a biomarker for disease.

Conclusion

In conclusion, YARS2 is a protein that is involved in the regulation of protein synthesis in various tissues and cells. Its potential as a drug target or biomarker has been identified, and further studies are needed to determine its role in the regulation of protein synthesis and its potential as a therapeutic agent. Targeting YARS2 with small molecules or antibodies has the potential to be a novel drug or biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Protein Name: Tyrosyl-tRNA Synthetase 2

Functions: Catalyzes the attachment of tyrosine to tRNA(Tyr) in a two-step reaction: tyrosine is first activated by ATP to form Tyr-AMP and then transferred to the acceptor end of tRNA(Tyr)

The "YARS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about YARS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets